Mesin L, Ersching J, Victora GD. Germinal center B cell dynamics. Immunity. 2016;45:471–82 http://www.ncbi.nlm.nih.gov/pubmed/27653600.
Article
CAS
Google Scholar
Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15:172–84 https://pubmed.ncbi.nlm.nih.gov/25712152/.
Article
CAS
Google Scholar
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11 http://www.ncbi.nlm.nih.gov/pubmed/10676951.
Article
CAS
Google Scholar
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90 http://www.ncbi.nlm.nih.gov/pubmed/29713087.
Article
CAS
Google Scholar
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–407 http://www.ncbi.nlm.nih.gov/pubmed/29641966.
Article
CAS
Google Scholar
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–69 http://www.nejm.org/doi/abs/10.1056/NEJMoa041869.
Article
CAS
Google Scholar
Mondello P, Fama A, Larson MC, Feldman AL, Villasboas JC, Yang ZZ, et al. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J. 2021;11:130 https://pubmed.ncbi.nlm.nih.gov/34267181/.
Article
Google Scholar
Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021;11:1468–89 https://pubmed.ncbi.nlm.nih.gov/33541860/.
Article
CAS
Google Scholar
Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021;39(10):1422–37 http://www.cell.com/article/S1535610821004517/fulltext Elsevier.
Article
CAS
Google Scholar
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 2020;10:440–59 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-19-0116.
Article
CAS
Google Scholar
Meyer SN, Scuoppo C, Vlasevska S, Bal E, Holmes AB, Holloman M, et al. Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. Immunity Cell Press. 2019;51:535–547.e9.
CAS
Google Scholar
Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, et al. Molecular and genetic characterization of MHC deficiency identifies ezh2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9:546–63 https://pubmed.ncbi.nlm.nih.gov/30705065/.
Article
Google Scholar
Mondello P, Ansell SM, Nowakowski GS. Immune epigenetic crosstalk between malignant B cells and the tumor microenvironment in B cell lymphoma. Front Genet. 2022;13:826594 https://pubmed.ncbi.nlm.nih.gov/35237302/.
Article
CAS
Google Scholar
Mondello P, Ansell SM. PHOENIX rises: genomic-based therapies for diffuse large B cell lymphoma. Cancer Cell. 2021;39:1570–2 https://pubmed.ncbi.nlm.nih.gov/34739842/.
Article
CAS
Google Scholar
Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529–42 https://pubmed.ncbi.nlm.nih.gov/25367570/.
Article
CAS
Google Scholar
Jacobsen JT, Hu W, Castro TBR, Solem S, Galante A, Lin Z, et al. Expression of Foxp3 by T follicular helper cells in end-stage germinal centers. Science. 2021;373:eabe5146 https://pubmed.ncbi.nlm.nih.gov/34437125/.
Article
CAS
Google Scholar
Zhou DM, Xu YX, Zhang LY, Sun Y, Wang ZY, Yuan YQ, et al. The role of follicular T helper cells in patients with malignant lymphoid disease. Hematology. 2017;22:412–8 https://pubmed.ncbi.nlm.nih.gov/28281408/.
Article
CAS
Google Scholar
Cha Z, Gu H, Zang Y, Wang Z, Li J, Huang W, et al. The prevalence and function of CD4+CXCR5+Foxp3+ follicular regulatory T cells in diffuse large B cell lymphoma. Int Immunopharmacol. 2018;61:132–9 https://pubmed.ncbi.nlm.nih.gov/29870918/.
Article
CAS
Google Scholar
Mintz MA, Cyster JG. T follicular helper cells in germinal center B cell selection and lymphomagenesis. Immunol Rev. 2020;296:48–61 https://pubmed.ncbi.nlm.nih.gov/32412663.
Article
CAS
Google Scholar
Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O, Semana G, et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-κB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol. 2008;181:1001–11 https://www.jimmunol.org/content/181/2/1001.
Article
CAS
Google Scholar
Brady MT, Hilchey SP, Hyrien O, Spence SA, Bernstein SH. Mesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells. PLoS One. 2014;9:e97597 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0097597.
Article
Google Scholar
Calvo KR, Dabir B, Kovach A, Devor C, Bandle R, Bond A, et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood. 2008;112:3818–26 https://pubmed.ncbi.nlm.nih.gov/18682601/.
Article
CAS
Google Scholar
Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol. 2013;190:6681–93 http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1201363.
Article
CAS
Google Scholar
Pangault C, Amé-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010;24:2080–9 http://www.nature.com/articles/leu2010223.
Article
CAS
Google Scholar
Ma X, Zha J, He J, Chen L, Huang J, Wu W, et al. T follicular helper cell-mediated IL-21 production suppresses FOXP3 expression of T follicular regulatory-like cells in diffuse large B cell lymphoma patients. Hum Immunol. 2020;81:452–9 https://pubmed.ncbi.nlm.nih.gov/32534760/.
Article
CAS
Google Scholar
Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 2022;3:428–43 https://aacrjournals.org/bloodcancerdiscov/article/3/5/428/708353/Follicular-Lymphoma-Microenvironment.
Article
CAS
Google Scholar
Chaudhry A, Rudensky AY. Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Invest. 2013;123:939–44 https://pubmed.ncbi.nlm.nih.gov/23454755/.
Article
CAS
Google Scholar
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:986–92 https://pubmed.ncbi.nlm.nih.gov/12612578/.
Article
Google Scholar
Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64.
Article
CAS
Google Scholar
Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162–71 https://aacrjournals.org/cancerres/article/72/9/2162/584187/T-Regulatory-Cells-Key-Players-in-Tumor-Immune.
Article
CAS
Google Scholar
Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639–46 https://pubmed.ncbi.nlm.nih.gov/16403912/.
Article
CAS
Google Scholar
Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957–64 http://www.bloodjournal.org/cgi/doi/10.1182/blood-2006-04-018218.
Article
CAS
Google Scholar
Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637–50 https://aacrjournals.org/clincancerres/article/16/2/637/75610/A-Unifying-Microenvironment-Model-in-Follicular.
Article
CAS
Google Scholar
Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008;93:193–200 https://pubmed.ncbi.nlm.nih.gov/18223287/.
Article
CAS
Google Scholar
Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49:247–56 https://pubmed.ncbi.nlm.nih.gov/18231910/.
Article
CAS
Google Scholar
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8+ T-cell function by CD4+CD25 + regulatory T cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 2006;66:10145–52 https://pubmed.ncbi.nlm.nih.gov/17047079/.
Article
CAS
Google Scholar
Nakayama S, Yokote T, Akioka T, Hiraoka N, Nishiwaki U, Miyoshi T, et al. Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. Blood Adv. 2017;1:486–93 https://ashpublications.org/bloodadvances/article/1/8/486/15602/Infiltration-of-effector-regulatory-T-cells.
Article
CAS
Google Scholar
Yang ZZ, Kim HJ, Wu H, Jalali S, Tang X, Krull JE, et al. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma. Clin Cancer Res. 2020;26:5217–31 https://pubmed.ncbi.nlm.nih.gov/32631956/.
Article
Google Scholar
Tang X, Yang Z-Z, Kim HJ, Anagnostou T, Yu Y, Wu X, et al. Phenotype, function, and clinical significance of CD26+ and CD161+Tregs in splenic marginal zone lymphoma. Clin Cancer Res. 2022;28:4322–35 https://pubmed.ncbi.nlm.nih.gov/35686915/.
Article
CAS
Google Scholar
Profitós-Pelejà N, Santos JC, Marín-Niebla A, Roué G, Ribeiro ML. Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas. Cancers (Basel). 2022;14:860 https://pubmed.ncbi.nlm.nih.gov/35205606/.
Article
Google Scholar
Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, MacDougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713–20 https://pubmed.ncbi.nlm.nih.gov/19786615/.
Article
CAS
Google Scholar
Pandiyan P, Younes SA, Ribeiro SP, Talla A, McDonald D, Bhaskaran N, et al. Mucosal regulatory T cells and T helper 17 cells in HIV-associated immune activation. Front Immunol. 2016;7:228 https://pubmed.ncbi.nlm.nih.gov/27379092/.
Article
Google Scholar
Grygorowicz MA, Borycka IS, Nowak E, Paszkiewicz-Kozik E, Rymkiewicz G, Błachnio K, et al. Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation. Clin Exp Med. 2017;17:193–207 https://pubmed.ncbi.nlm.nih.gov/26961690/.
Article
CAS
Google Scholar
Tarantelli C, Argnani L, Zinzani PL, Bertoni F. PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. Cancers (Basel). 2021;13:5535 /pmc/articles/PMC8582887.
Article
CAS
Google Scholar
Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, et al. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity 11 medical and health sciences 1107 immunology. J Immunother Cancer. 2018;6:1–14 https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0457-0.
Google Scholar
Jin H, Zhou Y, Wang L. The mechanism of rapamycin in promoting asthmatic regulatory T cell differentiation and function. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50:621–6 https://pubmed.ncbi.nlm.nih.gov/34986526/.
Google Scholar
Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–82 https://pubmed.ncbi.nlm.nih.gov/18759926/.
Article
CAS
Google Scholar
Larson RC, Maus M, v. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145–61 https://pubmed.ncbi.nlm.nih.gov/18759926.
Article
CAS
Google Scholar
Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933–59 https://pubmed.ncbi.nlm.nih.gov/33811125/.
Article
CAS
Google Scholar
Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel). 2021;13:1440 https://pubmed.ncbi.nlm.nih.gov/33809974/.
Article
CAS
Google Scholar
Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, et al. A phase I study of the combination of rituximab and ipilimumab in patients with relapsed/ refractory B-cell lymphoma. Clin Cancer Res. 2019;25:7004–13 https://pubmed.ncbi.nlm.nih.gov/31481504/.
Article
CAS
Google Scholar
Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAAS, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120–33 https://pubmed.ncbi.nlm.nih.gov/28803728/.
Article
CAS
Google Scholar
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8 https://pubmed.ncbi.nlm.nih.gov/28803728/.
Article
Google Scholar
Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 https://pubmed.ncbi.nlm.nih.gov/28197366/.
Article
Google Scholar
Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6:27359–77 https://pubmed.ncbi.nlm.nih.gov/26318293/.
Article
Google Scholar
Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15:6446–53 https://pubmed.ncbi.nlm.nih.gov/19808874/.
Article
CAS
Google Scholar
Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–53 https://pubmed.ncbi.nlm.nih.gov/16286920/.
Article
CAS
Google Scholar
Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, et al. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. Sci Rep. 2015;5:15659 https://pubmed.ncbi.nlm.nih.gov/26493689/.
Article
CAS
Google Scholar
Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9:681–92 https://pubmed.ncbi.nlm.nih.gov/28653573/.
Article
CAS
Google Scholar
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57 https://pubmed.ncbi.nlm.nih.gov/19011627.
Article
CAS
Google Scholar
Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The Immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell. 2014;26:923–37 https://pubmed.ncbi.nlm.nih.gov/25465800/.
Article
CAS
Google Scholar
Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200:108–19 https://pubmed.ncbi.nlm.nih.gov/31828774/.
Article
Google Scholar
Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol. 2001;2:415–22 https://pubmed.ncbi.nlm.nih.gov/11323695/.
Article
CAS
Google Scholar
Youngblood B, Hale JS, Kissick HT, Ahn E, Xu X, Wieland A, et al. Effector CD8 T cells dedifferentiate into long-lived memory cells. Nature. 2017;552:404–9 https://pubmed.ncbi.nlm.nih.gov/29236683/.
Article
CAS
Google Scholar
Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol. 2021;22:809–19 https://pubmed.ncbi.nlm.nih.gov/34140679/.
Article
CAS
Google Scholar
Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134:17–32 http://www.ncbi.nlm.nih.gov/pubmed/21711350.
Article
CAS
Google Scholar
Alotaibi F, Vincent M, Min WP, Koropatnick J. Reduced CD5 on CD8+ T cells in tumors but not lymphoid organs is associated with increased activation and effector function. Front Immunol. 2021;11:584937 https://pubmed.ncbi.nlm.nih.gov/33584650/.
Article
Google Scholar
Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19:665–74 https://pubmed.ncbi.nlm.nih.gov/31570879/.
Article
CAS
Google Scholar
Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13:338–97 https://pubmed.ncbi.nlm.nih.gov/17255259/.
Article
Google Scholar
Alvaro T, Lejeune M, Salvadó M-T, Lopez C, Jaén J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350–7 http://ascopubs.org/doi/10.1200/JCO.2006.06.4766.
Article
Google Scholar
Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27:1470–6 http://ascopubs.org/doi/10.1200/JCO.2008.18.0513.
Article
Google Scholar
Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska TP, Jalali S, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1 + T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8:61425–39 https://pubmed.ncbi.nlm.nih.gov/28977875/.
Article
Google Scholar
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, de Marzo A, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Investig. 2007;117:3383–92 https://pubmed.ncbi.nlm.nih.gov/17932562/.
Article
CAS
Google Scholar
Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in Cancer. Trends Immunol. 2019;40:310–27 https://pubmed.ncbi.nlm.nih.gov/30890304.
Article
CAS
Google Scholar
Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12:76 https://pubmed.ncbi.nlm.nih.gov/31300030/.
Article
Google Scholar
Taskinen M, Karjalainen-Lindsberg M-L, Nyman H, Eerola L-M, Leppä S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13:5784–9 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-07-0778.
Article
CAS
Google Scholar
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875–85 https://pubmed.ncbi.nlm.nih.gov/20220182/.
Article
CAS
Google Scholar
Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood. 2010;115:5053–6 https://pubmed.ncbi.nlm.nih.gov/20375314/.
Article
CAS
Google Scholar
Shen L, Li H, Shi Y, Wang D, Gong J, Xun J, et al. M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma. Sci Rep. 2016;6:30347 https://pubmed.ncbi.nlm.nih.gov/27464733/.
Article
CAS
Google Scholar
Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;11:1731.
Article
CAS
Google Scholar
Petty AJ, Yang Y. Tumor-associated macrophages in hematologic malignancies: new insights and targeted therapies. Cells. 2019;8:1526 https://pubmed.ncbi.nlm.nih.gov/32849616/.
Article
CAS
Google Scholar
Papin A, Tessoulin B, Bellanger C, Moreau A, le Bris Y, Maisonneuve H, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019;33(2442):2453 https://pubmed.ncbi.nlm.nih.gov/30940906/.
Google Scholar
Valero JG, Matas-Céspedes A, Arenas F, Rodriguez V, Carreras J, Serrat N, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021;35:2635–49 https://pubmed.ncbi.nlm.nih.gov/33731849/.
Article
CAS
Google Scholar
DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–82 https://pubmed.ncbi.nlm.nih.gov/30718830/.
Article
CAS
Google Scholar
Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699–713 https://linkinghub.elsevier.com/retrieve/pii/S0092867410008925.
Article
CAS
Google Scholar
Eladl E, Tremblay-Lemay R, Rastgoo N, Musani R, Chen W, Liu A, et al. Role of CD47 in hematological malignancies. J Hematol Oncol. 2020;13:96 https://pubmed.ncbi.nlm.nih.gov/32677994/.
Article
Google Scholar
Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118:4890–901 https://ashpublications.org/blood/article/118/18/4890/29362/Extranodal-dissemination-of-nonHodgkin-lymphoma.
Article
CAS
Google Scholar
Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021;6:10 https://pubmed.ncbi.nlm.nih.gov/33431788/.
Article
CAS
Google Scholar
Yan-Li L, Hu Q-Q, Wen Z-F, Li Q, Zhai Z-M. CCR2 expression promotes diffuse large B lymphoma cell survival and invasion. Lab Investig. Lab Invest. 2022;102:1377–88. https://pubmed.ncbi.nlm.nih.gov/35851856/.
Wu X, Singh R, Hsu DK, Zhou Y, Yu S, Han D, et al. A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti–PD-1 in a murine model of cutaneous T-cell lymphoma (CTCL). J Investig Dermatol. 2020;140:1390–400 https://pubmed.ncbi.nlm.nih.gov/31945344/.
Article
CAS
Google Scholar
Ludwig N, Rubenich DS, Zaręba Ł, Siewiera J, Pieper J, Braganhol E, et al. Potential roles of tumor cell-and stroma cell-derived small extracellular vesicles in promoting a pro-angiogenic tumor microenvironment. Cancers (Basel). 2020;12:3599 https://pubmed.ncbi.nlm.nih.gov/33276428/.
Article
CAS
Google Scholar
Poles WA, Nishi EE, de Oliveira MB, Eugênio AIP, de Andrade TA, Campos AHFM, et al. Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly. Cancer Immunol Immunother. 2019;68:269–82 https://pubmed.ncbi.nlm.nih.gov/30430204/.
Article
CAS
Google Scholar
Moradi-Chaleshtori M, Bandehpour M, Soudi S, Mohammadi-Yeganeh S, Hashemi SM. In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes. Cancer Immunol Immunother. 2021;70:1323–39 https://pubmed.ncbi.nlm.nih.gov/33140190/.
Article
CAS
Google Scholar
Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425 https://aacrjournals.org/cancerres/article/67/1/425/532949/The-Terminology-Issue-for-Myeloid-Derived.
Article
CAS
Google Scholar
Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019;12:84 https://pubmed.ncbi.nlm.nih.gov/31438991/.
Article
Google Scholar
Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208–20 https://pubmed.ncbi.nlm.nih.gov/26858199/.
Article
CAS
Google Scholar
Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015;168:689–700 https://pubmed.ncbi.nlm.nih.gov/25376846/.
Article
CAS
Google Scholar
Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G, et al. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016;7:27676–88 https://pubmed.ncbi.nlm.nih.gov/27050283/.
Article
Google Scholar
Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, le Priol J, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 2016;128:1081–92 https://pubmed.ncbi.nlm.nih.gov/27338100/.
Article
CAS
Google Scholar
Tadmor T, Fell R, Polliack A, Attias D. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol. 2013;31:65–71 https://pubmed.ncbi.nlm.nih.gov/22714941/.
Article
Google Scholar
Ren WH, Zhang XR, Li WB, Feng Q, Feng HJ, Tong Y, et al. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag Res. 2019;11:4023–40 https://pubmed.ncbi.nlm.nih.gov/31190980/.
Article
CAS
Google Scholar
Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691–702 https://pubmed.ncbi.nlm.nih.gov/17101732/.
Article
CAS
Google Scholar
Xu Z, Ji J, Xu J, Li D, Shi G, Liu F, et al. MiR-30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B-cell lymphoma. FEBS J. 2017;284:2410–24 https://pubmed.ncbi.nlm.nih.gov/28605567/.
Article
CAS
Google Scholar
Grauers Wiktorin H, Nilsson MS, Kiffin R, Sander FE, Lenox B, Rydström A, et al. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer Immunol Immunother. 2019;68:163–74 https://pubmed.ncbi.nlm.nih.gov/30315349.
Article
CAS
Google Scholar
Locatelli SL, Careddu G, Serio S, Consonni FM, Maeda A, Viswanadha S, et al. Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kd/G inhibitor RP6530. Clin Cancer Res. 2019;25:1098–112 https://pubmed.ncbi.nlm.nih.gov/30352904/.
Article
CAS
Google Scholar
Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig. 2016;126:3130–44 https://pubmed.ncbi.nlm.nih.gov/27454297/.
Article
Google Scholar
Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64:817–29 https://pubmed.ncbi.nlm.nih.gov/25850344/.
Article
CAS
Google Scholar
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98 https://pubmed.ncbi.nlm.nih.gov/27550820.
Article
CAS
Google Scholar
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48 https://pubmed.ncbi.nlm.nih.gov/15882617/.
Article
CAS
Google Scholar
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115 https://pubmed.ncbi.nlm.nih.gov/30470818/.
Article
CAS
Google Scholar
Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014;158:564–78 https://pubmed.ncbi.nlm.nih.gov/25083868/.
Article
CAS
Google Scholar
Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15:637–46 https://pubmed.ncbi.nlm.nih.gov/23708000/.
Article
CAS
Google Scholar
Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017;14:662–74 https://pubmed.ncbi.nlm.nih.gov/28626234/.
Article
CAS
Google Scholar
Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol. 1999;277:C1–9.
Article
CAS
Google Scholar
Pandey S, Mourcin F, Marchand T, Nayar S, Guirriec M, Pangault C, et al. IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood. 2017;129:2507–18 https://pubmed.ncbi.nlm.nih.gov/28202459/.
Article
CAS
Google Scholar
Grégoire M, Guilloton F, Pangault C, Mourcin F, Sok P, Latour M, et al. Neutrophils trigger a NF-ΚB dependent polarization of tumorsupportive stromal cells in germinal center B-cell lymphomas. Oncotarget. 2015;6:16471–87 https://pubmed.ncbi.nlm.nih.gov/26158216/.
Article
Google Scholar
Guilloton F, Caron G, Ménard C, Pangault C, Amé-Thomas P, Dulong J, et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood. 2012;119:2556–67 http://ashpublications.org/blood/article-pdf/119/11/2556/1350217/zh801112002556.pdf.
Article
CAS
Google Scholar
Haro M, Orsulic S. A paradoxical correlation of cancer-associated fibroblasts with survival outcomes in B-cell lymphomas and carcinomas. Front Cell Dev Biol. 2018;6:98 https://pubmed.ncbi.nlm.nih.gov/30211161/.
Article
Google Scholar
Stelling A, Hashwah H, Bertram K, Manz MG, Tzankov A, Müller A. The tumor suppressive TGF-b/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood. 2018;131:2235–46 https://pubmed.ncbi.nlm.nih.gov/29615404/.
Article
CAS
Google Scholar
Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-β: from conception to autoimmunity and infection. Cold Spring Harb Perspect Biol. 2017;9:a0222236 https://pubmed.ncbi.nlm.nih.gov/28108486.
Article
Google Scholar
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503–10 https://pubmed.ncbi.nlm.nih.gov/18425107/.
Article
CAS
Google Scholar
Harel-Bellan A, Quillet A, Marchiol C, DeMars R, Tursz T, Fradelizi D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci U S A. 1986;83:5688–92 https://pubmed.ncbi.nlm.nih.gov/2426704/.
Article
CAS
Google Scholar
McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016;5:e1226720 https://pubmed.ncbi.nlm.nih.gov/27853650/.
Article
Google Scholar
Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immun. 2022:1–16 https://www.nature.com/articles/s41577-022-00732-1.
Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–8 https://pubmed.ncbi.nlm.nih.gov/3951539/.
Article
Google Scholar
Seaman WE, Sleisenger M, Eriksson E, Koo GC. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol. 1987;138:4539–44.
CAS
Google Scholar
Street SEA, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and γδ T cells. J Exp Med. 2004;199:879–84 https://pubmed.ncbi.nlm.nih.gov/15007091/.
Article
CAS
Google Scholar
Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13:459–63 https://pubmed.ncbi.nlm.nih.gov/11282985/.
Article
CAS
Google Scholar
Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity. 2020;53:1215–29 https://pubmed.ncbi.nlm.nih.gov/33220234/.
Article
CAS
Google Scholar
Marcus A, Mao AJ, Lensink-Vasan M, Wang LA, Vance RE, Raulet DH. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49:754–63 https://pubmed.ncbi.nlm.nih.gov/30332631/.
Article
CAS
Google Scholar
Varn FS, Wang Y, Mullins DW, Fiering S, Cheng C. Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment. Cancer Res. 2017;77:1271–82 https://pubmed.ncbi.nlm.nih.gov/28126714/.
Article
CAS
Google Scholar
Cózar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11:34–44 https://pubmed.ncbi.nlm.nih.gov/33277307/.
Article
Google Scholar
Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S, et al. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res. 2019;7:1162–74.
Article
CAS
Google Scholar
Castriconi R, Cantoni C, della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor β1 inhibits expression of NKP30 and NKG2d receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100:4120–5 https://pubmed.ncbi.nlm.nih.gov/12646700/.
Article
CAS
Google Scholar
Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18:1004–15 https://pubmed.ncbi.nlm.nih.gov/28759001/.
Article
CAS
Google Scholar
Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257–70.
Article
CAS
Google Scholar
Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78:1003–16 https://pubmed.ncbi.nlm.nih.gov/29229601/.
Article
CAS
Google Scholar
Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006;214:229–38 https://pubmed.ncbi.nlm.nih.gov/17100888/.
Article
CAS
Google Scholar
Kerdiles Y, Ugolini S, Vivier E. T cell regulation of natural killer cells. J Exp Med. 2013;210:1065–8 https://pubmed.ncbi.nlm.nih.gov/23733834/.
Article
CAS
Google Scholar
Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106:17858–63 https://pubmed.ncbi.nlm.nih.gov/19815499/.
Article
CAS
Google Scholar
Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15:531–8 https://pubmed.ncbi.nlm.nih.gov/24658051/.
Article
Google Scholar
Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Investig. 2018;128:4654–68 https://pubmed.ncbi.nlm.nih.gov/30198904/.
Article
Google Scholar
Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1 þ NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6:1548–60 https://pubmed.ncbi.nlm.nih.gov/30282672/.
Article
CAS
Google Scholar
Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C, et al. The SIRPα-CD47 immune checkpoint in NK cells. J Exp Med. 2021;218:e20200839 https://pubmed.ncbi.nlm.nih.gov/33416832/.
Article
CAS
Google Scholar
Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286–94 https://pubmed.ncbi.nlm.nih.gov/20460501/.
Article
CAS
Google Scholar
Beldi-Ferchiou A, Lambert M, Dogniaux S, Vély F, Vivier E, Olive D, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7:72961–77 https://pubmed.ncbi.nlm.nih.gov/27662664/.
Article
Google Scholar
Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36:6143–53 https://pubmed.ncbi.nlm.nih.gov/28692048/.
Article
CAS
Google Scholar
Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131:1809–19 https://pubmed.ncbi.nlm.nih.gov/29449276/.
Article
CAS
Google Scholar
Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723–32 https://pubmed.ncbi.nlm.nih.gov/29915296/.
Article
CAS
Google Scholar
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731–43 https://pubmed.ncbi.nlm.nih.gov/30503213/.
Article
Google Scholar
McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med. 2009;206:1899–911 https://pubmed.ncbi.nlm.nih.gov/19652017/.
Article
CAS
Google Scholar
Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. 2019;177:1701–13 https://pubmed.ncbi.nlm.nih.gov/31155232/.
Article
CAS
Google Scholar
Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, et al. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Adv. 2018;2:1459–60 https://pubmed.ncbi.nlm.nih.gov/29941459/.
Article
CAS
Google Scholar
Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73:1777–86 https://pubmed.ncbi.nlm.nih.gov/23302231/.
Article
CAS
Google Scholar
Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer. Immunol Res. 2019;7:363–75 https://pubmed.ncbi.nlm.nih.gov/30651290/.
CAS
Google Scholar
Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147 https://pubmed.ncbi.nlm.nih.gov/25340009/.
Article
Google Scholar
Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557–75 https://www.nature.com/articles/s41568-022-00491-0.
Article
CAS
Google Scholar
Eberl G, Colonna M, Santo JPD, McKenzie ANJ. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348:aaa6566 https://pubmed.ncbi.nlm.nih.gov/25999512/.
Article
Google Scholar
Tait Wojno ED, Beamer CA. Isolation and identification of innate lymphoid cells (ILCs) for immunotoxicity testing. Methods Mol Biol. 2018;1803:353–70 https://pubmed.ncbi.nlm.nih.gov/29882149/.
Article
Google Scholar
Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity. 2014;41:354–65 https://pubmed.ncbi.nlm.nih.gov/25238093/.
Article
CAS
Google Scholar
McKenzie ANJ, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity. 2014;41:366–74 https://pubmed.ncbi.nlm.nih.gov/25238094/.
Article
CAS
Google Scholar
Bernink JH, Peters CP, Munneke M, te Velde AA, Meijer SL, Weijer K, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14(14):221–9 https://pubmed.ncbi.nlm.nih.gov/23334791/.
Article
CAS
Google Scholar
Mackay LK, Kallies A. Transcriptional regulation of tissue-resident lymphocytes. Trends Immunol. 2017;38:94–103 https://pubmed.ncbi.nlm.nih.gov/27939451/.
Article
CAS
Google Scholar
Tait Wojno ED, Artis D. Emerging concepts and future challenges in innate lymphoid cell biology. J Exp Med. 2016;213:2229–48 https://pubmed.ncbi.nlm.nih.gov/27811053/.
Article
Google Scholar
Licona-Limón P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14:536–42 https://pubmed.ncbi.nlm.nih.gov/23685824/.
Article
Google Scholar
Hwang YY, McKenzie ANJ. Innate lymphoid cells in immunity and disease. Adv Exp Med Biol. 2013;785:9–26 https://pubmed.ncbi.nlm.nih.gov/23456833/.
Article
CAS
Google Scholar
Huntington ND, Carpentier S, Vivier E, Belz GT. Innate lymphoid cells: parallel checkpoints and coordinate interactions with T cells. Curr Opin Immunol. 2016;38:86–93 https://pubmed.ncbi.nlm.nih.gov/26736074/.
Article
CAS
Google Scholar
Mjösberg J, Bernink J, Peters C, Spits H. Transcriptional control of innate lymphoid cells. Eur J Immunol. 2012;42:1916–23 https://pubmed.ncbi.nlm.nih.gov/22865043/.
Article
Google Scholar
Klose CSN, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17:765–74 https://pubmed.ncbi.nlm.nih.gov/27328006/.
Article
CAS
Google Scholar
Klose CSN, Flach M, Möhle L, Rogell L, Hoyler T, Ebert K, et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell. 2014;157:340–56 https://pubmed.ncbi.nlm.nih.gov/24725403/.
Article
CAS
Google Scholar
Constantinides MG, McDonald BD, Verhoef PA, Bendelac A. A committed precursor to innate lymphoid cells. Nature. 2014;508:397–401 https://pubmed.ncbi.nlm.nih.gov/24509713/.
Article
CAS
Google Scholar
Bal SM, Bernink JH, Nagasawa M, Groot J, Shikhagaie MM, Golebski K, et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol. 2016;17:636–45 https://pubmed.ncbi.nlm.nih.gov/27111145/.
Article
CAS
Google Scholar
Ohne Y, Silver JS, Thompson-Snipes LA, Collet MA, Blanck JP, Cantarel BL, et al. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. Nat Immunol. 2016;17:646–55 https://pubmed.ncbi.nlm.nih.gov/27111142/.
Article
CAS
Google Scholar
Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8:593 https://pubmed.ncbi.nlm.nih.gov/28928446/.
Article
Google Scholar
Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5–producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188:703–13 https://pubmed.ncbi.nlm.nih.gov/22174445/.
Article
CAS
Google Scholar
Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker Interleukin-33. Sci Rep. 2016;6:30555 https://pubmed.ncbi.nlm.nih.gov/27619158/.
Article
CAS
Google Scholar
Zaiss DMW, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42:216–26 https://pubmed.ncbi.nlm.nih.gov/25692699/.
Article
CAS
Google Scholar
Bando JK, Nussbaum JC, Liang H-E, Locksley RM. Type 2 innate lymphoid cells constitutively express arginase-I in the naïve and inflamed lung. J Leukoc Biol. 2013;94:877–84 https://pubmed.ncbi.nlm.nih.gov/23924659/.
Article
CAS
Google Scholar
Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of il-12- and il-15-responsive ifn-γ-producing cells. Immunity. 2013;38:769–81 https://pubmed.ncbi.nlm.nih.gov/23453631/.
Article
CAS
Google Scholar
Bernink JH, Krabbendam L, Germar K, de Jong E, Gronke K, Kofoed-Nielsen M, et al. Interleukin-12 and -23 control plasticity of Cd127+ group 1 and group 3 innate lymphoid cells in the intestinal Lamina Propria. Immunity. 2015;43:146–60.
Article
CAS
Google Scholar
Pearson C, Thornton EE, McKenzie B, Schaupp AL, Huskens N, Griseri T, et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. Elife. 2016;5:e10066 https://pubmed.ncbi.nlm.nih.gov/26780670/.
Article
Google Scholar
Griseri T, Arnold IC, Pearson C, Krausgruber T, Schiering C, Franchini F, et al. Granulocyte macrophage Colony-stimulating factor-activated eosinophils promote Interleukin-23 driven chronic colitis. Immunity. 2015;43:187–99 https://pubmed.ncbi.nlm.nih.gov/26200014/.
Article
CAS
Google Scholar
Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407:348–54 https://pubmed.ncbi.nlm.nih.gov/21396350/.
Article
CAS
Google Scholar
Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 2011;71:1263–71 https://pubmed.ncbi.nlm.nih.gov/21303976/.
Article
CAS
Google Scholar
King RL, Goodlad JR, Calaminici M, Dotlic S, Montes-Moreno S, Oschlies I, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020;476:647–65 https://pubmed.ncbi.nlm.nih.gov/31863183/.
Article
Google Scholar
Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176:210–21 https://pubmed.ncbi.nlm.nih.gov/27739058/.
Article
CAS
Google Scholar
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20:216–28 http://www.ncbi.nlm.nih.gov/pubmed/30630772.
Article
CAS
Google Scholar
Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. 2022;13:1–20 https://www.nature.com/articles/s41467-022-30050-y.
Article
Google Scholar
Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869–81 http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-10-673236.
Article
CAS
Google Scholar
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–9 http://www.ncbi.nlm.nih.gov/pubmed/21179087.
Article
CAS
Google Scholar
Challa-Malladi M, Lieu YK, Califano O, Holmes A, Bhagat G, Murty V v., et al. Combined genetic inactivation of Beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B-cell lymphoma. Cancer Cell 2011;20:728. /pmc/articles/PMC3660995/.
Article
CAS
Google Scholar
Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377–81 https://pubmed.ncbi.nlm.nih.gov/21368758/.
Article
CAS
Google Scholar
Marcelis L, Antoranz A, Delsupehe AM, Biesemans P, Ferreiro JF, Debackere K, et al. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother. 2020;69:1751–66 https://pubmed.ncbi.nlm.nih.gov/32335702/.
Article
CAS
Google Scholar
Guo J, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Ther. 2021;28:1075–87 https://pubmed.ncbi.nlm.nih.gov/33500535/.
Article
CAS
Google Scholar
Mondello P, Brea EJ, de Stanchina E, Toska E, Chang AY, Fennell M, et al. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. JCI Insight. 2017;2:e90196 http://www.ncbi.nlm.nih.gov/pubmed/28352655.
Article
Google Scholar
Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018–29 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-17-0613.
Article
CAS
Google Scholar
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833–843.e5 http://www.ncbi.nlm.nih.gov/pubmed/28552327.
Article
CAS
Google Scholar
Mondello P, Mian M, Bertoni F. Primary central nervous system lymphoma: novel precision therapies. Crit Rev Oncol Hematol. 2019;141:139–45 http://www.ncbi.nlm.nih.gov/pubmed/31295667.
Article
Google Scholar
Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020;183:363–76 https://pubmed.ncbi.nlm.nih.gov/33007267/.
Article
CAS
Google Scholar
Tavaré R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76:73–82 https://pubmed.ncbi.nlm.nih.gov/26573799/.
Article
Google Scholar
Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, et al. CD8-targeted PET imaging of tumor-infiltrating T cells in patients with Cancer: a phase i first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 Minibody. J Nucl Med. 2022;63:720–6 https://pubmed.ncbi.nlm.nih.gov/34413145/.
CAS
Google Scholar
Gosmann D, Russelli L, Weber WA, Schwaiger M, Krackhardt AM, D’Alessandria C. Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy. EJNMMI Res. 2022;12:5 https://pubmed.ncbi.nlm.nih.gov/35099641/.
Article
CAS
Google Scholar